Phase 2 N=48 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Pancreatic Acinar Cell Carcinoma · Pancreatic Ductal Adenocarcinoma · Recurrent Pancreatic Carcinoma
Primary: Progression-free Survival Using RECIST v. 1.1 — 4.9; 5.2 months
Phase 2 N=45 Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Rate of Participants Achieving Complete Response or Partial Response to Therapy. — 6; 25; 0 participants
Phase 1 N=4 Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Phase 2 N=32 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants
Phase 2 N=42 Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Pancreatic Cancer
Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=30 Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Pancreatic Cancer
Primary: Progression Free Survival — 2.07 months
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Phase 1 N=21 Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=96 Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
Treatment
Primary: 1-year Progression Free Survival Rate — 9; 18 Participants
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 2 N=7 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Progression-free Survival — 2.5; 4.0 months — p=0.15
Phase 2 N=28 Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
Pancreatic Cancer
Primary: Median Overall Survival (OS) — 42 months
N/A N=36 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 2 N=72 Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment — 37 percentage of participants
Phase 2 N=49 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Pancreatic Cancer
Primary: Progression-free Survival — 9.2; 8.9 months
Phase 2 N=23 CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Pancreatic Cancer
Primary: Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects — 10; 1000…
Phase 2 N=19 Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants
Phase 2 N=20 A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects — 2 Participants — p=0.824
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=39 Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Phase 2 N=18 Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Pancreatic Cancer
Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants